{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:29:17Z","timestamp":1781018957335,"version":"3.54.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41390-025-04305-5","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T06:13:04Z","timestamp":1753251184000},"page":"958-963","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Paradoxical psoriasis in pediatric tumor necrosis factor-\u03b1 inhibitor therapy database"],"prefix":"10.1038","volume":"99","author":[{"given":"Yurong","family":"Piao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingfeng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongxin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huawei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"4305_CR1","doi-asserted-by":"publisher","first-page":"e30275","DOI":"10.1371\/journal.pone.0030275","volume":"7","author":"KJ Aaltonen","year":"2012","unstructured":"Aaltonen, K. J. et al. Systematic review and meta-analysis of the efficacy and safety of existing Tnf blocking agents in treatment of rheumatoid arthritis. PLoS One 7, e30275 (2012).","journal-title":"PLoS One"},{"key":"4305_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02466-4","volume":"9","author":"C Conrad","year":"2018","unstructured":"Conrad, C. et al. Tnf blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat. Commun. 9, 25 (2018).","journal-title":"Nat. Commun."},{"key":"4305_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40272-021-00440-8","volume":"23","author":"N Rosenwasser","year":"2021","unstructured":"Rosenwasser, N., Lee, D., Sidbury, R. & Zhao, Y. Paradoxical psoriasis in children receiving anti-Tnfalpha treatment for inflammatory\/autoimmune disease. Paediatr. Drugs 23, 131\u2013141 (2021).","journal-title":"Paediatr. Drugs"},{"key":"4305_CR4","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.3389\/fimmu.2018.02746","volume":"9","author":"A Mylonas","year":"2018","unstructured":"Mylonas, A. & Conrad, C. Psoriasis: classical vs. paradoxical. The Yin-Yang of Tnf and type I interferon. Front. Immunol. 9, 2746 (2018).","journal-title":"Front. Immunol."},{"key":"4305_CR5","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/rheumatology\/kel346","volume":"46","author":"M Gattorno","year":"2007","unstructured":"Gattorno, M. et al. Distinct expression pattern of Ifn-alpha and Tnf-alpha in juvenile idiopathic arthritis synovial tissue. Rheumatology46, 657\u2013665 (2007).","journal-title":"Rheumatology"},{"key":"4305_CR6","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/j.1365-2133.2009.09329.x","volume":"161","author":"J Seneschal","year":"2009","unstructured":"Seneschal, J. et al. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br. J. Dermatol 161, 1081\u20131088 (2009).","journal-title":"Br. J. Dermatol"},{"key":"4305_CR7","doi-asserted-by":"crossref","unstructured":"Maronese, C. A., Costanzo, A., Gilliet, M. & Marzano, A. V. Paradoxical psoriasis: from its many faces to possible shared therapeutic targets. J. Invest. Dermatol. 144, 2084\u20132085 (2024).","DOI":"10.1016\/j.jid.2024.03.007"},{"key":"4305_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M15-0729","volume":"164","author":"I Cleynen","year":"2016","unstructured":"Cleynen, I. et al. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann. Intern. Med. 164, 10\u201322 (2016).","journal-title":"Ann. Intern. Med."},{"key":"4305_CR9","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/ajg.2015.205","volume":"110","author":"E Freling","year":"2015","unstructured":"Freling, E. et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-Tnf therapy in inflammatory bowel disease: a 14-year experience. Am. J. Gastroenterol. 110, 1186\u20131196 (2015).","journal-title":"Am. J. Gastroenterol."},{"key":"4305_CR10","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1517\/14740338.4.5.929","volume":"4","author":"M Hauben","year":"2005","unstructured":"Hauben, M., Madigan, D., Gerrits, C. M., Walsh, L. & Van Puijenbroek, E. P. The role of data mining in pharmacovigilance. Expert Opin. Drug Saf. 4, 929\u2013948 (2005).","journal-title":"Expert Opin. Drug Saf."},{"key":"4305_CR11","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1002\/sim.2473","volume":"25","author":"GN Noren","year":"2006","unstructured":"Noren, G. N., Bate, A., Orre, R. & Edwards, I. R. Extending the methods used to screen the who drug safety database towards analysis of complex associations and improved accuracy for rare events. Stat. Med. 25, 3740\u20133757 (2006).","journal-title":"Stat. Med."},{"key":"4305_CR12","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","volume":"25","author":"A Szarfman","year":"2002","unstructured":"Szarfman, A., Machado, S. G. & O\u2019Neill, R. T. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the Us Fda\u2019s spontaneous reports database. Drug Saf. 25, 381\u2013392 (2002).","journal-title":"Drug Saf."},{"key":"4305_CR13","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s40264-018-0706-7","volume":"41","author":"C Tieu","year":"2018","unstructured":"Tieu, C. & Breder, C. D. A critical evaluation of safety signal analysis using algorithmic standardised MedDRA queries. Drug Saf. 41, 1375\u20131385 (2018).","journal-title":"Drug Saf."},{"key":"4305_CR14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate, A. & Evans, S. J. Quantitative signal detection using spontaneous Adr reporting. Pharmacoepidemiol. Drug Saf. 18, 427\u2013436 (2009).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"4305_CR15","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1097\/MIB.0b013e31828075bd","volume":"19","author":"KE Kip","year":"2013","unstructured":"Kip, K. E. et al. Tumor necrosis factor alpha antagonist-associated psoriasis in inflammatory diseases: an analysis of the Fda adverse event reporting system. Inflamm. Bowel Dis. 19, 1164\u20131172 (2013).","journal-title":"Inflamm. Bowel Dis."},{"key":"4305_CR16","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jamadermatol.2023.0549","volume":"159","author":"J Eickstaedt","year":"2023","unstructured":"Eickstaedt, J. et al. Paradoxical psoriasiform eruptions in children receiving tumor necrosis factor alpha inhibitors. JAMA Dermatol 159, 637\u2013642 (2023).","journal-title":"JAMA Dermatol"},{"key":"4305_CR17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/ard.2007.087288","volume":"68","author":"MJ Harrison","year":"2009","unstructured":"Harrison, M. J. et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 68, 209\u2013215 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"4305_CR18","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/ijd.13691","volume":"56","author":"M Havmose","year":"2017","unstructured":"Havmose, M. & Thomsen, S. F. Development of paradoxical inflammatory disorders during treatment of psoriasis with Tnf inhibitors: a review of published cases. Int J. Dermatol 56, 1087\u20131102 (2017).","journal-title":"Int J. Dermatol"},{"key":"4305_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/acr.24100","volume":"73","author":"LH Buckley","year":"2021","unstructured":"Buckley, L. H., Xiao, R., Perman, M. J., Grossman, A. B. & Weiss, P. F. Psoriasis associated with tumor necrosis factor inhibitors in children with inflammatory diseases. Arthritis Care Res.73, 215\u2013220 (2021).","journal-title":"Arthritis Care Res."},{"key":"4305_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/pde.13081","volume":"34","author":"JB Eickstaedt","year":"2017","unstructured":"Eickstaedt, J. B. et al. Psoriasis and psoriasiform eruptions in pediatric patients with inflammatory bowel disease treated with anti-tumor necrosis factor alpha agents. Pediatr. Dermatol. 34, 253\u2013260 (2017).","journal-title":"Pediatr. Dermatol."},{"key":"4305_CR21","doi-asserted-by":"publisher","first-page":"e174","DOI":"10.1111\/pde.12820","volume":"33","author":"R Romiti","year":"2016","unstructured":"Romiti, R., Araujo, K. M., Steinwurz, F. & Denadai, R. Anti-tumor necrosis factor alpha-related psoriatic lesions in children with inflammatory bowel disease: case report and systematic literature review. Pediatr. Dermatol. 33, e174\u2013e178 (2016).","journal-title":"Pediatr. Dermatol."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04305-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04305-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04305-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:21:12Z","timestamp":1774527672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04305-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4305"],"URL":"https:\/\/doi.org\/10.1038\/s41390-025-04305-5","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"9 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Since the FAERS database is accessible to the public and patient records are anonymized and deidentified, ethical clearance and informed consent are not required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}